A researcher working in a laboratory at BeiGene's research and development centre in Beijing, China. Photo: Bloomberg
Hong Kong could become biotech listing hub, says BeiGene boss as Chinese drug maker gears up for US$1 billion flotation
The cancer treatment firm is the first to seek a secondary listing in the city since the bourse overhauled its rules in a bid to attract big technology companies
Topic |
Hong Kong Stock Exchange
A researcher working in a laboratory at BeiGene's research and development centre in Beijing, China. Photo: Bloomberg